MorphoSys AG has announced the appointment of Tim Demuth as chief research and development officer, effective 1 October, and the retirement of Malte Peters. Dr Demuth will lead development of the company’s oncology pipeline. He joins MorphoSys from Pieris Pharmaceuticals Inc where he has been chief medical officer. Prior to Pieris he led global clinical development of oncology products at Merck KGaA where he was responsible for a pipeline of small molecules, antibodies and antibody-drug conjugates.
Dr Demuth received his MD and PhD degrees from Johannes Gutenberg University in Mainz, Germany.
MorphoSys announced the appointment on 1 September 2022.
Copyright 2022 Evernow Publishing Ltd